Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | GUCY1A1 | Q02108 | 13/20 | 0.43 |
| ▸ | GUCY1B1 | Q02153 | 13/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000157 | 0.95 | RAB9A (0.52) | RAB9AMEN1NPC1KMT2AKEAP1 | |
| SCHEMBL3998724 | 0.94 | RAB9A (0.53) | RAB9AMEN1NPC1KMT2AKEAP1 | |
| SCHEMBL3998934 | 0.90 | KEAP1 (0.48) | RAB9AMEN1NPC1KMT2AKEAP1 | |
| SCHEMBL4000533 | 0.89 | KEAP1 (0.51) | RAB9AMEN1NPC1KMT2AKEAP1 | |
| SCHEMBL3999377 | 0.89 | PTGER4 (0.41) | RAB9AMEN1NPC1KMT2AATM | |
| SCHEMBL3994003 | 0.89 | KEAP1 (0.50) | RAB9AMEN1NPC1KMT2AKEAP1 | |
| SCHEMBL3995334 | 0.89 | KEAP1 (0.55) | RAB9AMEN1NPC1KMT2AKEAP1 | |
| SCHEMBL4004399 | 0.88 | KEAP1 (0.51) | RAB9AMEN1NPC1KMT2AKEAP1 | |
| SCHEMBL3998260 | 0.87 | KEAP1 (0.51) | RAB9AMEN1NPC1KMT2AKEAP1 | |
| SCHEMBL4002493 | 0.87 | KEAP1 (0.54) | RAB9AMEN1NPC1KMT2AKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | claimed |
| WO-2015095515-A1 | SGC ACTIVATORS FOR THE TREATMENT OF GLAUCOMA | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |